biostudies-literatureUnknown13Gu SCShanghai Shenkang Hospital Development CenterFoundation for Innovative Research Groups of the National Natural Science Foundation of ChinaNational Key Research and Development Program of ChinaScience and Technology Innovation Plan of Shanghai Science and Technology Commission<b>Background:</b> Pingchan granule (PCG) is a traditional Chinese medicine for treating Parkinson's disease (PD). <b>Objective:</b> This study aimed at evaluating the efficacy and safety of PCG for motor and non-motor symptoms of PD. <b>Methods:</b> In this multicenter, randomized, double-blind, placebo-controlled trial, 292 participants with mild-to-moderate PD were included and followed for 36 weeks (24 week treatment, 12-week follow-up after intervention), randomly assigned at a 1:1 ratio to receive PCG or placebo. The primary outcomes included the severity of motor symptoms assessed by the Unified Parkinson's disease Rating Scale (UPDRS) part 3 (UPDRS-III) score and the rate of disease progression assessed by the total UPDRS score. Secondary outcomes included non-motor symptoms assessFrontiers in pharmacology739194https://www.ebi.ac.uk/biostudies/studies/S-EPMC8914044biostudies-literaturePingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.PMC8914044Zhao SRYe QZhang YYuan CXLiu ZGGu SCGao CWang CDZhou JfalsePingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.<b>Background:</b> Pingchan granule (PCG) is a traditional Chinese medicine for treating Parkinson's disease (PD). <b>Objective:</b> This study aimed at evaluating the efficacy and safety of PCG for motor and non-motor symptoms of PD. <b>Methods:</b> In this multicenter, randomized, double-blind, placebo-controlled trial, 292 participants with mild-to-moderate PD were included and followed for 36 weeks (24 week treatment, 12-week follow-up after intervention), randomly assigned at a 1:1 ratio to receive PCG or placebo. The primary outcomes included the severity of motor symptoms assessed by the Unified Parkinson's disease Rating Scale (UPDRS) part 3 (UPDRS-III) score and the rate of disease progression assessed by the total UPDRS score. Secondary outcomes included non-motor symptoms assess2022-01-01T00:00:00Z20222025-04-04T20:23:49.601Z2025-04-04T20:23:49.601ZS-EPMC89140443528189010.3389/fphar.2022.739194